ReviewIn vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
References (113)
- et al.
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs
Drug Metab Pharmacokinet
(2008) - et al.
Mechanisms of renal anionic drug transport
Eur. J. Pharmacol.
(2008) - et al.
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
Pharmacol. Ther.
(2006) - et al.
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Pharmacol. Ther.
(1997) Interspecies scaling of renally secreted drugs
Life Sci.
(1998)- et al.
Determination of brush border membrane vesicle orientation using monoclonal antibodies recognizing extracytoplasmic and cytoplasmic domains of neutral endopeptidase-24.11
Anal. Biochem.
(1988) - et al.
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers
Gastroenterology
(2001) - et al.
Transporters as a determinant of drug clearance and tissue distribution
Eur. J. Pharm. Sci.
(2006) - et al.
Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2)
J. Biol. Chem.
(2002) - et al.
Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice
J. Biol. Chem.
(2006)
The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane
Kidney. Int.
(2008)
Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles
Biochim. Biophys. Acta.
(1984)
Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1
FEBS Lett.
(1997)
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H( + )-organic cation antiporters
Biochem. Pharmacol.
(2007)
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs
Cell
(1994)
In Vivo Evaluation of P-glycoprotein Function at the Blood–brain Barrier in Nonhuman Primates Using [11C]Verapamil
J. Pharmacol. Exp. Ther.
(2006)
Mechanisms and clinical implications of renal drug excretion
Drug Metab. Rev.
(2001)
Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs
Annu. Rev. Pharmacol. Toxicol.
(2005)
Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
Drug Metab. Dispos.
(1999)
Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data
J. Pharmacol. Exp. Ther.
(2001)
Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3)
(2008)
Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers
Pharm Res
(1993)
Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter
Drug Metab. Dispos.
(1997)
Use of Ca2 + modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes
J. Pharmacol. Exp. Ther.
(1999)
In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance
J. Pharmacol. Exp. Ther.
(2008)
Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes
Drug Metab. Dispos.
(2008)
An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development
Experience within Hoffmann La Roche. Clin. Pharmacokinet.
(1997)
Species similarities and differences in pharmacokinetics
Drug Metab. Dispos.
(1995)
Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices
J. Pharmacol. Exp. Ther.
(2007)
Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices
J. Pharmacol. Exp. Ther.
(2007)
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions
J. Pharmacol. Exp. Ther.
(2002)
Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat
J. Pharmacol. Exp. Ther.
(2003)
Studies on the orientation of brush-border membrane vesicles
Biochem. J.
(1978)
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic up-take of pitavastatin in humans
J. Pharmacol. Exp. Ther.
(2004)
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
Drug Metab. Dispos.
(2006)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pharmacogenet. Genomics.
(2006)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
Clin. Pharmacol. Ther.
(2005)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
J. Clin. Pharmacol.
(2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
Clin. Pharmacol. Ther.
(2007)
Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A
J. Pharmacol. Exp. Ther.
(2003)
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Clin. Pharmacol. Ther.
(2007)
SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers
Clin. Pharmacol. Ther.
(2007)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics
Clin. Pharmacol. Ther.
(2003)
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
Clin. Pharmacol. Ther.
(2006)
SLCO1B1 variants and statin-induced myopathy–a genomewide study
N. Engl. J. Med.
(2008)
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17
Pharmacogenet. Genomics.
(2005)
Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy
J. Hum. Genet.
(2006)
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
Clin. Pharmacol. Ther.
(2006)
Cited by (195)
Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance
2022, Pharmacology and TherapeuticsEffect of liver disease on pharmacokinetics
2021, Atkinson's Principles of Clinical PharmacologySpecies differences in the drug–drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs
2020, European Journal of Pharmaceutical SciencesKirchhoff’s Laws and Hepatic Clearance, Well-Stirred Model – Is There Common Ground?
2023, Drug Metabolism and Disposition
Copyright © 2009 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.